Details of Disease

General Information of Disease (ID: DISLPORP)

• Disease Name: Community-acquired pneumonia
• Disease Class: CA40: Pneumonia
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISLPORP: Community-acquired pneumonia
• ICD Code:
  ICD-11: ICD-11: CA40.Z
  Expand ICD-11: 'CA40.Z
  Expand ICD-9: 4.80E+23

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Lefamulin	DME6G97	Approved	NA	[1]
Nemonoxacin	DM0S9Z1	Approved	Small molecular drug	[2]
Sivelestat sodium hydrate	DMOSJD0	Phase 4	Small molecular drug	[3]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ceftobiprole	DMM76GL	Phase 3	Small molecular drug	[4]
JNJ-32729463	DMQD1GN	Phase 2	Small molecular drug	[5]
Nafithromycin	DMWAE7U	Phase 2	Small molecular drug	[6]
KBP-7072	DMXJDXH	Phase 1	Small molecular drug	[7]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] Nemonoxacin: first global approval. Drugs. 2014 Aug;74(12):1445-53.
• [3] Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
• [4] ClinicalTrials.gov (NCT03439124) Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT01198626) Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT02903836) Phase II Study of Oral Nafithromycin in CABP. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT04532957) A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects. U.S. National Institutes of Health.